Compare
Longevity companies, side by side.
Every company profiled on variis, on the same table. Exchange, category, market cap, status, all sourced and dated.
13 of 35 companies. Scroll horizontally on narrow screens.
| Attribute | Alliance Healthcare Group LimitedSGX Catalist | AMILI | Clearbridge Health LimitedSGX Catalist | Cordlife Group LimitedSGX | Hummingbird Bioscience | IHH Healthcare BerhadSGX | Mirxes Holding Company LimitedHKEX | Nuevocor Pte Ltd | OUE Healthcare LimitedSGX Catalist | Raffles Medical Group LtdSGX | Singapore Institute of Advanced Medicine Holdings LtdSGX Catalist | TalkMed Group Limited | Thomson Medical Group LimitedSGX |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exchange | SGX Catalist | – | SGX Catalist | SGX | – | SGX | HKEX | – | SGX Catalist | SGX | SGX Catalist | – | SGX |
| Ticker | SGX Catalist:MIJ | – | SGX Catalist:1H3 | SGX:P8A | – | SGX:Q0F | HKEX:2629 | – | SGX Catalist:5WA | SGX:BSL | SGX Catalist:9G2 | – | SGX:A50 |
| Secondary listing | – | – | – | – | – | Bursa Malaysia (primary listing, IHH) | – | – | – | – | – | – | – |
| Market cap | Approx. SGD 33 million (market cap SGD 32.69m at a share price of SGD 0.158, quote dated 3 July 2026) | – | Approximately S$6.4m (July 2026, stockanalysis.com; share price S$0.001, 6.44bn shares outstanding) | – | – | – | HK$3.66bn (approx US$470m) as at 31 March 2026 per stockanalysis.com, down from a HK$8.29bn debut valuation on 23 May 2025; no verified mid-2026 quote retrieved | – | – | Approximately SGD 1.73 billion (17 July 2026, share price SGD 0.94) | approx. SGD 47 million (17 July 2026) | – | – |
| Category | Diagnostics | Diagnostics | Diagnostics | Regenerative medicine | Pharma | Healthtech | Diagnostics | Regenerative medicine | Healthtech | Healthtech | Diagnostics | Healthtech | Healthtech |
| Headquarters | Singapore | Singapore (89 Science Park Drive, #03-09, The Rutherford, Science Park 1) | Singapore | Singapore | The Galen, 61 Science Park Road, #06-15, Singapore 117525 | Kuala Lumpur, Malaysia | Singapore | Singapore (1 North Buona Vista Link, #10-07 Elementum, Singapore 139691), with offices in Fort Washington, Pennsylvania, USA and Paris, France | Singapore (6 Shenton Way, Singapore 068809) | Singapore | Singapore | Singapore (101 Thomson Road, #09-02 United Square, Singapore 307591) | Singapore |
| Status | Active | Private | Active | Active | Private | Active | Active | Private | Active | Active | Active | Delisted | Active |
| Longevity exposure | Qualifies on both limbs: listed on SGX Catalist under MIJ and headquartered in Singapore (25 Bukit Batok Crescent). Alliance is an investment holding company running an integrated Singapore healthcare network: GP clinic services (My Family Clinic), specialist care, managed healthcare solutions sold to corporates and insurers, pharmaceutical services, radiology, home care (JagaMe) and a digital health app (HeyAlly). It states access to more than 2,000 in-house and partner medical facilities in Singapore, and had 395 employees with a July-June fiscal year. The longevity-relevant activity is preventive and occupational health screening delivered at scale through corporate health plans and the GP network, plus imaging and teleconsultation that route screening findings into follow-up care. It is a care-delivery and screening distribution business, not a developer of ageing-biology therapeutics or biomarker tests, so exposure is to the preventive-screening and primary-care layer rather than to any geroscience intervention. | Microbiome science company running a multi-ethnic Asian gut microbiome biobank and reference database, which it uses to interpret consumer and clinician-ordered stool tests. Commercial output is diagnostic rather than therapeutic: a gut microbiome test kit and an enhanced version, four targeted probiotic formulations (immune-metabolic, complete, cognitive, digestive), microbiome restoration therapy, and AMILI Optimise Plus, a metabolic health programme that pairs microbiome profiling with continuous glucose monitoring and nutritionist input. Distribution runs through a partner clinic network. Longevity relevance is indirect: it sits in the metabolic-health and personalised-nutrition layer, measuring and modifying a biomarker set (gut composition, glycaemic response) associated with cardiometabolic risk, not intervening in ageing biology directly. Efficacy claims for microbiome-guided nutrition remain contested in the literature; the company's own database size claims are self-reported and not independently verified here. | Operates medical clinics and diagnostic services across Singapore, the Philippines and Hong Kong, including imaging, general health screening and vaccination. Its longevity relevance is limited and indirect: it is a clinic and screening operator, not a company developing ageing-biology interventions or aging-specific biomarker panels. The relevant exposure is preventive health screening infrastructure in Southeast Asia, which sits adjacent to the longevity clinic market. Financial condition is weak: FY2025 revenue of S$9.93m was flat year on year while net loss widened to S$12.91m, and the shares trade at S$0.001 on the SGX Catalist board with a market capitalisation of roughly S$6.4m. Include only with that caveat. | Cordlife collects, processes and cryogenically stores umbilical cord blood and cord tissue for private clients across several Asian markets, operating storage facilities rather than developing therapies. Its longevity relevance is as infrastructure for cell-based and regenerative medicine: banked haematopoietic stem cells are held against future transplant or therapeutic use. It is a storage and services business, not a therapeutics developer, and it does not run clinical programmes in ageing biology. Inclusion is on the listing limb (SGX Mainboard) and the Singapore headquarters, both confirmed. Fundamentals should be treated as unconfirmed: the company is under active Singapore Ministry of Health regulatory restriction and its FY2025 accounts carry a disclaimer of opinion. | A Singapore-headquartered antibody drug developer. It designs monoclonal antibodies and antibody-drug conjugates against targets it selects computationally, then develops them for cancer and autoimmune disease. Current clinical assets are HMBD-001 (anti-HER3 antibody) and HMBD-501 (a HER3-directed antibody-drug conjugate, dosed in its first Phase I patient in January 2026). It has also out-licensed programmes: HMBD-002 (anti-VISTA) to Percheron Therapeutics in June 2025, and an undisclosed-target antibody to Immunome in January 2025. Its longevity relevance is indirect rather than direct. It does not work on ageing biology, senescence, metabolic ageing or healthspan endpoints. The connection is that cancer is a leading age-related cause of death, so better-targeted oncology therapeutics extend life in an older population. Read as an oncology biotech that sits in the SG/AU universe on headquarters grounds, not as a geroscience company. | Operates a private hospital network of 89 hospitals across 10 countries (Malaysia, Singapore, Turkiye, India, China, Hong Kong, Brunei, Bulgaria, North Macedonia, Netherlands, Serbia), including the Mount Elizabeth, Gleneagles and Parkway brands in Singapore. Its longevity relevance is delivery-side rather than therapeutic: it is the largest listed vehicle for age-related clinical care in Asia, with revenue concentrated in cardiology, oncology and orthopaedics, the specialties that scale with an ageing population. It also runs an SGD 80 million innovation fund backing startups in cancer diagnostics, digital health, proton therapy, mental health and sleep disorders. It does not develop geroprotective drugs or biological-age interventions. Inclusion is confirmed under limb (a): SGX secondary line Q0F verified on a live SGX healthcare sector listing. | Develops and sells blood-based microRNA diagnostic tests for early cancer detection. Its lead product, GASTROClear, is a 12-biomarker blood panel for gastric cancer screening; it also markets LUNGClear for lung cancer and Fortitude infectious-disease assays. The longevity relevance is early detection rather than any ageing-biology intervention: catching cancer at a screenable, asymptomatic stage in high-risk adults. Qualifies for the variis universe on the headquarters limb (Singapore), not the exchange limb, as it is listed on HKEX rather than SGX or ASX. | Clinical-stage genetic medicines company developing gene therapies for inherited cardiomyopathies, using a mechanobiology approach that targets the mechanical stress signalling inside failing heart muscle cells rather than correcting the mutated gene directly. Lead asset NVC-001 is an AAV-delivered therapy for LMNA-related dilated cardiomyopathy, an aggressive genetic heart-muscle disease with no targeted treatment. Longevity relevance is disease-specific rather than general: it aims to halt progression of a condition that causes heart failure and early death in carriers, not to modify ageing biology broadly. Both Singapore HQ and incorporation as a Pte Ltd confirmed on the company site, so it meets limb (b) of the inclusion rule. | Qualifies on both limbs: listed on SGX Catalist under 5WA and headquartered in Singapore. It is an investment holding company that owns, operates and invests in healthcare businesses across Singapore, China, Myanmar, Indonesia and Japan, running hospitals and specialist clinics, supplying medical equipment and pharmaceuticals, and holding healthcare property and development assets. Parent is OUE Limited. Its longevity relevance is indirect and infrastructural rather than biological: it is a private healthcare services operator, not a developer of ageing-targeted therapeutics or diagnostics. The nearest direct link is its stated push into specialised care and an integrative medicine offering combining traditional and Western treatment, which sits adjacent to preventive and wellness-oriented care. There is no disclosed geroscience, senolytic, biological-age testing or longevity-clinic programme. Treat it as a delivery-channel holding in the SG universe, not an intervention developer. Financial scale was not verified: the shares traded around SGD 0.03 on 17 July 2026 per StockAnalysis, but no market capitalisation figure was retrieved, so that field is left null rather than estimated. | An integrated private healthcare provider, not a longevity biotech. Founded 1976 and headquartered at Raffles Hospital, 585 North Bridge Road, Singapore, it runs family medicine clinics, specialist centres, hospitals, dental and Chinese medicine practices, insurance and healthcare products across Singapore, China, Vietnam, Cambodia and Japan. The longevity-relevant part is a preventive and chronic-care line rather than the group as a whole: health screening packages, an executive medical centre, statutory health checks, corporate health programmes covering more than 7,000 corporate clients, and chronic disease management delivered through its primary care network. That makes it the closest SGX-listed proxy for a clinical healthspan business, but the revenue base is conventional hospital and clinic services, and the company makes no ageing-biology or lifespan-extension claim. Treat it as delivery infrastructure for preventive medicine, not as an intervention developer. | Operates a single-site Singapore medical centre built around advanced imaging and radiation oncology. Two reported segments: medical diagnostics and treatments (cancer diagnostics, nuclear medicine, general health screening, aesthetic services) and radiation therapy and medical oncology (proton beam therapy, photon radiation therapy, medical oncology). Its stated clinical focus spans cancer, neurodegenerative and cardiovascular disease detection. The longevity-relevant part is the diagnostics and imaging arm: high-resolution and nuclear-medicine imaging plus paid health screening is early-detection infrastructure, the same category as preventive screening plays. The proton-beam oncology business is treatment for existing disease, not a longevity intervention, and is the larger capital commitment. There is no geroscience, biomarker-of-ageing, or therapeutic-development activity here. It is a small, loss-making clinical operator: FY2025 revenue SGD 15.71m, down 5.6% year on year, with a net loss of SGD 27.05m, and a market capitalisation under SGD 50m. Note the corporate site www.sam.com.sg did not resolve on repeated attempts, so the business description above rests on exchange-data aggregators rather than company disclosure. | Runs private medical oncology and palliative care practices in Singapore, delivered mainly through Parkway Cancer Centre, with sub-specialty coverage of breast, head and neck, gastro-intestinal, uro-gynaecological and haematological cancers, plus ancillary health services, medical technology services and some overseas operations. The longevity relevance is indirect and delivery-side rather than mechanistic: it is late-stage disease treatment and supportive care, not an ageing-biology intervention. Inclusion rule is met on both limbs (Singapore-headquartered, and formerly SGX Mainboard listed). It is no longer investable on public markets: the shares were delisted with effect from 15 September 2025 after a scheme-of-arrangement privatisation by TW Troy Limited. The former SGX counter code was 5G3; the ticker field is left null because that security no longer trades. The claim that the acquiring vehicle sits under pan-Asian oncology group Tamarind Health was not confirmed by the sources retrieved here, so it is not asserted. | Operator of private hospitals and clinics, with the group's distinctive concentration in women's health, fertility and maternity care. Its Singapore assets include Thomson Medical Centre and a network of women's clinics, fertility/IVF services and paediatric centres; it also operates in Malaysia (Thomson Hospital Kota Damansara) and Vietnam (FV Hospital, acquired 2023). The longevity-relevant limb is reproductive ageing: IVF and fertility treatment address declining ovarian reserve and age-related fertility loss in an ageing, low-birth-rate region. This is clinical service delivery, not geroscience research; the group does not develop ageing-directed therapeutics or biomarkers. Inclusion is on listing and HQ grounds (SGX-listed, Singapore-headquartered), with fertility as the thematic tie rather than any lifespan or healthspan intervention. |
| Recent inflection | FY2025 (year ended 30 June 2025): revenue rose 13.43% to SGD 77.12 million and net earnings rose 111.74% to SGD 1.52 million, per StockAnalysis financial summary; the shares subsequently traded up around 32% over the trailing year to July 2026 from an all-time low of SGD 0.088 on 7 January 2026. | On 21 April 2026, Calbee launched its Body Granola personalised nutrition service in Singapore with AMILI supplying the gut microbiome testing component, extending AMILI from direct-to-consumer testing into a consumer packaged goods partnership (NutraIngredients, 22 April 2026). | FY2025 results (year ended 31 December 2025, adopted at the AGM on 23 April 2026) showed revenue of S$9.93m, essentially flat year on year, with net loss widening to S$12.91m, roughly 258% worse than 2024. The company has since continued issuing shares at sub-cent prices, including an allotment of 2.1m shares at S$0.0018 in June 2026. | On 23 April 2026, ahead of its 27 April 2026 AGM, Cordlife disclosed that its independent auditors had issued a disclaimer of opinion on the financial statements for the year ended 31 December 2025, citing unresolved regulatory and legal matters and an inability to verify opening balances as at 1 January 2025. This followed the Ministry of Health's one-year suspension of its licence to collect, test, process or store new cord blood units, effective 26 November 2025, and an MOH directive to replace the Chief Governance Officer and review laboratory records for roughly 160 cord blood units collected since January 2025. Source: Minichart AGM report, 23 April 2026. | 6 January 2026: first patient dosed in the Phase I clinical trial of HMBD-501 in patients with advanced HER3-expressing solid malignancies (company news page, hummingbirdbioscience.com/news). | 13 July 2026: IHH set out a scaled-up India programme via its Fortis Healthcare subsidiary, targeting 10,000 beds by 2030 (roughly 8,000 visible through brownfield expansion), naming India as a global business services hub, and directing its SGD 80 million innovation fund toward AI, precision medicine and advanced oncology technology. Reported by Business Today. | 9 October 2025: China's NMPA granted GASTROClear Class III IVD registration, making it the first non-invasive blood test approved for gastric cancer screening in China, cleared for high-risk adults aged 45 to 74 on the basis of a 9,472-subject prospective trial across seven Chinese academic centres (Mirxes media release). | On 10 June 2025 the company announced FDA clearance of its IND for NVC-001 in LMNA-related dilated cardiomyopathy, clearing the way for first-in-human clinical work. This followed the close of a US$45m Series B on 6 May 2025 raised to fund that clinical development, per the company's own newsroom (https://www.nuevocor.com/news). | At its annual general meeting on 24 April 2026 (minutes lodged with SGX on 22 May 2026), management reiterated a three-part strategy of an asset-light model, strategic partnerships and regional Asian expansion, and flagged a shift toward specialised care including a planned integrative medicine service combining traditional and Western treatment. Source: SGX-hosted AGM minutes, https://links.sgx.com/FileOpen/OUEH%20-%20Minutes%20of%20AGM%20held%20on%2024%20April%202026.ashx?App=Announcement&FileID=889933 | FY2025 (year ended 31 December 2025) results released 22 February 2026: revenue of SGD 765.6 million, up 1.8% on FY2024's SGD 752.4 million, with net income of SGD 70.6 million, up 13.4% on SGD 62.2 million, so margin expansion rather than top-line growth drove the year. The stock nonetheless traded near its 52-week low of SGD 0.90 in July 2026. Source: stockanalysis.com SGX:BSL financials and quote pages, and the SGinvestors announcement calendar showing the 22 February 2026 full-year results release. | FY2025 results (financial year ended 31 December 2025) showed revenue of SGD 15.71m, down 5.63% year on year, with a net loss of SGD 27.05m, narrower than FY2024. The shares traded at SGD 0.027 on 17 July 2026, down 6.9% year to date, with the next earnings report scheduled for 29 August 2026 (stockanalysis.com, retrieved 19 July 2026). | Privatised by scheme of arrangement: shareholders approved the scheme on 15 July 2025, the Singapore court sanctioned it on 18 August 2025, SGX RegCo granted in-principle delisting approval on 21 August 2025, trading was suspended from 9.00 a.m. on 22 August 2025, and the shares were delisted from the SGX Mainboard with effect from 15 September 2025, with the acquirer named in the company announcement as TW Troy Limited (source: TalkMed SGX announcement dated 21 August 2025; delisting date confirmed by sginvestors.io). | Board and financial reset in early 2026: Tong Kooi Ong was appointed Independent Non-Executive Chairman effective 1 February 2026, succeeding Ng Ser Miang, in a move linked to the group's capital-intensive Johor Bay development in the Johor-Singapore Special Economic Zone. H1 2026 revenue rose to S$215.9m from S$201.9m a year earlier, with the net loss narrowing to S$10.2m, following an FY2025 loss driven by interest expense on the FV Hospital (Vietnam) acquisition and weaker Malaysian performance. (Reported via Simply Wall St; not independently confirmed against the SGX filing.) |
Not investment advice.